Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: rasagiline mesylate

« Back to Dashboard
Rasagiline mesylate is the generic ingredient in two branded drugs marketed by Teva, Apotex Inc, and Watson Labs Inc, and is included in three NDAs. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are seventeen drug master file entries for rasagiline mesylate. Two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: rasagiline mesylate

Drug Master File Entries: see list17
Suppliers: see list2
Therapeutic Class:Antiparkinson Agents
Formulation / Manufacturing:see details

Pharmacology for Ingredient: rasagiline mesylate

Tentative approvals for RASAGILINE MESYLATE

Applicant Application No. Form Dosage
<disabled><disabled>TABLET; ORAL0.5MG
<disabled><disabled>TABLET; ORAL1MG

Clinical Trials for: rasagiline mesylate

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline
Status: Completed Condition: Parkinson's Disease

A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease
Status: Completed Condition: Parkinson's Disease

Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.
Status: Completed Condition: Parkinson's Disease

ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
Status: Completed Condition: Parkinson's Disease

Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease
Status: Completed Condition: Parkinson's Disease

Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)
Status: Completed Condition: Multiple System Atrophy

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs Inc
rasagiline mesylate
TABLET;ORAL201823-002Jul 1, 2013DISCNNo<disabled><disabled>
rasagiline mesylate
TABLET;ORAL021641-001May 16, 2006RXNo<disabled><disabled>
rasagiline mesylate
TABLET;ORAL021641-001May 16, 2006RXNo7,815,942<disabled>YY<disabled>
rasagiline mesylate
TABLET;ORAL021641-002May 16, 2006RXYes<disabled><disabled>
rasagiline mesylate
TABLET;ORAL021641-001May 16, 2006RXNo5,453,446<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn